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Role of prostaglandins in tumour necrosis factor induced weight loss
S.M. Mahony & M.J. Tisdale
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Smmary Administration of either tumour necrosis factor alpha (TNF-2) or 16,16-dimethylprostaglandin E2
(PGE2) to female NMRI mice caused a decrease in body weight accompanied by a reduction in both food
and water intake and a decrease in carcass water content. A single injection of TNF-2 caused an enhanced
production of PGE2 by spleen cells from treated animals, that was significant within I h of treatment, and
persisted until at least 6h. These results suggest that the anorectic effect of TNF-z may be mediated by a
prostaglandin intermediate. Indomethacin (lOmgkg- ) administered 2h before TNF-a (7.5 x 107 Ukg-')
caused a significant reduction in the extent of weight loss and inhibited PgE2 production. Administration of
indomethacin 0.5-1.5h before the TNF-z had no significant effect on loss of body weight, but still inhibited
PgE2 production. Also PgE2 production was still enhanced in response to TNF-2 administered chronically,
despite the inability of prolonged TNF-z administration to produce continued loss of body weight. These
results suggest that prostaglandins are not involved in the anorectic effect of TNF-z.
The catabolic states associated with infection or endotoxemia
have been attributed to the production by phagocytic cells of
soluble proteins such as interleukin 1 and cachectin (Rouzer
& Cerami, 1980; Moldawer et al., 1987a; Cerami et al.,
1985). A high degree of homology has been shown to exist
between the N-terminal sequence of mouse cachectin and the
N-terminal sequence for human tumour necrosis factor-alpha
(TNF-x) (Beutler et al., 1985) and the catabolic states have
been extended to include also cancer-associated cachexia
(Beutler & Cerami, 1986). Severe weight loss and increased
mortality have been observed in mice bearing transgenic
tumours that persistently secrete human cachectin (Oliff et
al., 1987) and chronic administration of sublethal doses of
TNF-x to rats caused anorexia, weight loss, depletion of
body lipid and protein, a reduction of red blood cell mass,
leukocytosis and tissue inflammation (Tracey et al., 1988).
However, in a number of studies (Stovroff et al., 1988;
Mahony & Tisdale, 1988) administration of TNF-x caused a
loss in body weight accompanied by a drop in food and
water intake, which was only apparent over the first 24h,
after which animals became resistant to subsequent dosing.
In addition TNF-x has not been detectable in the serum of
patients with clinical cancer cachexia (Socher et al., 1988)
and in clinical tnrals of recombinant human TNF-x there was
no clinical evidence of accelerated cachexia, although
anorexia was present during administration (Sherman et al.,
1988). Also the effects on host metabolism produced by
TNF-:x appear to differ from that produced by a cachexia-
inducing tumour (Mahony et al., 1988).
The toxic and metabolic effects of TNF-:z can be blocked
by a single injection of the cyclo-oxygenase inhibitors indo-
methacin or ibuprofen before the TNF-x treatment
(Kettlehut et al., 1987). This suggests that some of the effects
of TNF-x may be mediated through a prostaglandin inter-
mediate in analogy with septic shock where large inacreases in
circulatory prostaglandins have been reported in a variety of
experimental models (Cook et al., 1980). In order to study
the role of prostaglandins in the mechanism of weight loss
induced by TNF-r we have used NMRI mice, a strain we
have utilised to passage a colon adenocarcinoma which
induces cachexia in recipient animals (Mahony et al., 1988).
Materials and methods
Animals
Pure strain female NMRI mice (age 6-8 weeks) were
purchased from Banting and Kingman (Hull, UK) and were
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fed ad lib a rat and mouse breeding diet (Pilsbury's
Birmingham, UK). All animals were given free access to
food and water and both food and water intake were
monitored daily.
TNF
Human recombinant TNF-x (6x IO7Umg-1) was kindly
donated by Boehringer Ingelheim Ltd (Bracknell, Berks,
UK) and was stored at 4-C. The endotoxin content was less
than 0.125EUml-1. Fresh solutions of TNF-2 were made
up daily in 0.9% NaCl and 200p1 of the appropriate
concentration (7.5 x 107Ukg-i) was injected into the tail
veins of female NMRI mice (19-22g). Controls were injected
with 200tl of 0.9% NaCI. Body weights and food and water
intake were monitored at the same time each day.
Body water content
Carcasses were heated at 80-C until a constant weight was
achieved. The carcasses were then reweighed and the water
content was determined from the difference between the wet
and dry weights.
Indomethacin administration
Fresh solutions of indomethacin (2mgml-1) in arachis oil
containing 10% DMSO were made up daily and 10mgkg-'
were injected i.p. into female NMRI mice (19-22g) 0.5-2h
before TNF-:x administration (7.5 x 107 Ukg- I i.v.). Controls
were injected with arachis oil containing 10% DMSO 2 h
before 0.9% NaCl administration (200up1, i.v.). Body weights
and food and water intake were monitored over a 24h
period and body composition analysis was performed. Urine
and faeces production was measured by placing animals in
metabolic cages throughout the experiment.
Prostaglandin E2 administration
Fresh solutions of 16,16-dimethyl PgE2 (0.125mgml-')
dissolved in triolein were made up daily in 0.9% NaCI and
were administered i.p. (0.5mgkg-1) at 6h intervals (11 a.m.,
5p.m., 1Ip.m.) into female NMRI mice (19+1 g). Controls
were injected with 200p1 of 0.9% NaCl containing triolein.
Body weights and food and water intake were monitored
over a 24h period and body water content was determined.
Mice were placed in metabolic cages throughout the
experiment and the urine and faeces production was
determined.
.c The Macmifan Press Ltd., 198952 S.M. MAHONY & MJ. TISDALE
PgE2 anal'sis
Male NMRI mice (20-26g) were injected i.v. with
7.5 x 107 Ukg- TNF-7 or 0.9% NaCI. At specified time
points after injection animals were killed by cervical
dislocation and the spleens rapidly removed and weighed.
Spleens were sliced on filter paper moistened with cold
0.85% NaCI and then placed in a 25ml flask containing 2ml
of Krebs-Ringer bicarbonate medium containing 1nmgnml-'
each of glucose and bovine serum albumin. The slices were
first incubated at 37-C for 20min in a gas phase of 5%
CO2/95% N2 and then transferred to flasks containing 5%
Co2/95% 02 for a further 15min. At the end of the
incubation spleens were removed and the medium was
immediately frozen at - 96°C and onlydefrosted immediately
before extraction.
For the determination of PgE2 1 ml of thawed medium
was removed, adjusted to pH 3 to 3.5 with 2N HC1 and
extracted twice with 3ml of ethyl acetate. The extract was
evaporated to dryness under a stream of nitrogen and
dissolved in 0.025M phosphate buffer, pH 6.8. containing
0.01 M EDTA, 0.9% NaCI, 0.3% bovine y-globulin, 0.005%
triton x 100 and 0.05% sodium azide and the concentration
of PgE2 was determined using a radioimmunoassay (NEN,
Dreieich, FR Germany).
Statistical analysis
All results were analysed statistically using the analysis of
vanance or F ratio.
Results
We have utilised PgE2 production by spleen cells rapidly
removed from TNF-x treated animals as an indirect method
of measuring prostaglandin production because of difficulties
in measuring plasma levels of PgE2 directly. The radio-
immunoassay utilised for these measurements had not
previously been tested on mouse plasma and our investi-
gations revealed an inhibition of the binding of PgE2 from
mouse plasma with the antibody used in the assay. The
results presented in Figure show an enhanced production
of PgE2 by spleen cells after administration of TNF-r
(7.5x 10 Ukg-1), which was significantly greater than saline
infused controls within I h after administration, and
remained elevated up to 6h after treatment. This suggests
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Fgre I Effect of a single i.v. injection of TNF-2
(7.5 x O'Ukg-1) on PgE, production by spleen cells. Spleens
were rapidly removed from control (E) and TNF-a (*) treated
animals and PgE2 production in vitro was determined by a
radioimmunoassay. The values represent means+s.e.m. for 5-6
animals. *PO.0001 from controls.
CD 13.0
@ 12.5
c
0
0
as 12-0
a
00
a
SAM PTE2
Figue 2 Effect of TNF-z and 16,16-dimethyl PgE2 adminis-
tration on body weight change (a), food (B) and water (E)
consumption (b) and body water content (c). Female NMRI
mice (19.0+l.Og) were given either a single i.v. injection ofTNF-
x (7.5 x 107 Ukg-1) or dimethyl PgE2 (0.5 mgkg-1) administered
i.p. at three 6-hourly intervals and the parameters were measured
as described in methods. The values represent means+s.e.m. for
nine animals. *PS0.001 from controls.
that some of the metabolic effects of TNF-x may be
mediated via prostaglandin production.
Administration of TNF-x (7.5x 107Ukg-') produced a
decrease in body weight within the first 24h after adminis-
tration (Figure 2a), accompanied by a decrease in food and
water intake (Figure 2b). Body composition analysis revealed
a decrease in the body water content of TNF-x treated mice,
when compared with saline infused controls (Figure 2c).
Essentially similar results were obtained after administration
of the stable PgE2 analogue 16,16-dimethyl PgE2 at a dose
of 0.5mgkg-' administered i.p. three times daily. No effect
was seen after a dose of 1.25mgkg- administered as a
single i.v. injection. Thus after 24h PgE2 treated animals
showed a reduction in body weight (Figure 2a) which was
similar to that produced by TNF-a in that it was
accompanied by a reduction in both food and water intake
(Figure 2b) and a decrease in the body water content (Figure
a
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Table I Effect of TNF-2 and indomethacin alone and in combination on body weight,
production by spleen cells
food and water intake and PgE2
PgE2
Bodi- weight Food intake Water intake (ngmg-I
Treatment change (g) (g) (mI) wet weight)
Controls, Lv. saline 0.00+0.17 4.39+026 7.04+0.46 0.69+0.11
i.v. saline+l0mgkg-1 indomethacin +0.19+0.13d 4.89+022 5.77+0.36 0.17+0.41
TNF-2 (7.5 x IO'Ukg-) -1.35 +0.14k 2.30+0.16a 3.40+0.33a 1.60+0.31a
TNF-a (7.5 x 17OUkg-')+ 10mgkg-' indomethacin
30min before TNF-x -1.63+0.19 1.63+0.49 4.5+0.33 0.44+0.17c
TNF-a (7.5 x 10' Ukg + 10mg kg indomethacin
1.5h before TNF-a -1.23+0.54 1.98+0.46 5.75+0.36 0.53+0.47c
TNF-x (7.5 x 10' Ukg + 10mgkg1 indomethacin
2h before TNF- -1.53+0.llb-c 2.76+0.17' 3.91 +0.4If 0.43±0.27c
Results represent means+&sei for 5-16 animals for each group.
aP<0.001 from controls; bpo0.005 from controls; CPO.OO1 from TNF-x alone: dPS0.001 from TNF-xiindomethacin 2h; 'P<0.05 from TNF-r 'PA0.OOI from indomethacin 2h.
2c). These results suggest that the effect of TNF-x on body
weight may be mediated via a prostaglandin intermediate,
and that it may be possible to reverse the effects by the
inhibition of prostaglandin synthesis.
Administration of indomethacin (10mgkg-1) 2h before a
single injection of TNF-x (7.5x 107 Ukg-1) caused a
significant reduction in the TNF-x induced weight loss
(Table I). The time of administration of indomethacin
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Figre 3 Effect of indomethacin on the body water content of
TNF-z treated mice. Animals were given either 0.9% NaCl i.v.,
7.5x l0'Ukg-' TNF-.c. i.v.. lOmgkg-1 indomethacin i.p. 2h
before 0.9% NaCl i.v., or 10mgkg-' indomethacin i.p. 2h
before 7.5 x107 Ukg-' TNF-a i.v. The values represent mean-
+s.e.m. for seven animals. *P<0.001 from TNF-2 treated ani-
mals. tP0.00l from saline injected controls.
appeared to be cnrtical since no weight reversal was observed
0.5 or 1.5h before the TNF-x (Table I). When compared
with indomethacin treated controls the decrease in water
intake in the 2h indomethacin/TNF-xz treated mice (32%)
was not as great as in the TNF-x treated mice compared
with saline infused controls (52%), although the food intake
was reduced to about the same extent in both cases (44%
and 48% respectively, Table I) compared with the respective
controls. There was a significant increase in food
consumption of the TNF-x/indomethacin treated mice when
compared with TNF-x treatment alone, and body
composition analysis showed an increase in the total body
water content of the TNF-x/indomethacin group when
compared with indomethacin alone (Figure 3). This
difference was not explained by decreased excretion of urine
(Table II). Animals treated with TNF-xz had a significant
reduction in the excretion of both urine and faeces,
indicating that the decrease in body water content did not
arise from a diuretic effect of TNF-ox. 16,16-Dimethyl PgE2
also caused a reduction in urine and faeces production
(Table II). Indomethacin had no effect on urine or faeces
production in control animals, although there was a small
increase in faeces production in TNF-2 treated animals.
The effect of indomethacin on PgE2 production by spleen
cells from TNF-x treated animals is shown in Table I. All
values were measured 2h after TNF-:x administration since
PgE2 production in response to TNF-x was significantly
elevated at this point (Figure 1). Indomethacin inhibited
PgE2 production in response to PgE2 irrespective of the time
of administration with respect to TNF-x, although the
reversal of body weight loss was highly dependent on the
time of administration (Table I). This suggests that
indomethacin did not reverse the TNF-z induced weight loss
as a result of inhibition of prostaglandin synthesis and that
prostaglandin production was not necessary for weight loss
to occur.
This conclusion was also substantiated by measurement of
Table n Effect of TNF-.ct indomethacin and 16.16-dimethyl PgE2 on excretion of urine and faeces
Urine Wet faeces Drn faeces Totalfluid
volume weight weight excretion
Treatment (ml) (g) (g) (ml)
Controls, i.v. saline 1.28+0.3 2.13+0.9 1.15+0.4 2.05+0.34
l0mgkg- 1 indomethacin 0.97+0.2 2.24+0.3 1.18+0.2 2.00+0.30
TNF-2 (7.5 x 107Ukg ) 0.44+0.2b 0.50+0.08a 0.32+0.06b 0.62+0.16c
TNF-2 (7.5xl07Ukg-1)+l0mgkg-1 indomethacin 0.66+0.2 0.80_0.13d'e 0.51_0.08d.e 0.95_026d
Dimethyl PgE2, 0.5mgkg-' 3xdaily 0.75+0.2 0.97+0.2O 0.34+0.1 lb 1.38+0.12'
Results are expressed as means+se.m for 6-7 animals per group. ap(0.05 from saline controls; bp<0.005 from saline controls; CP<0.001 from saline controls; dp<0.00I from
indomethacin controls; CP<0.005 from TNF-2 alone.
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PgE2 production by spleen cells when TNF-xz was adminis-
tered chronically. As previously reported (Mahony &
Tisdale, 1988), animals become resistant to subsequent
injections of TNF-:x after the first 24h with the body weight
increasing towards that of controls. At 24h PgE2 production
by spleen cells was 0.51 +0.04ngmg1 wet weight in controls
and 1.98+0.16ngmg'- wet weight in TNF-2 treated
animals, i.e. 3.9 times the control value. This difference was
maintained up to 5 days of TNF-:x administration (3.7 times
the control value) despite the fact that the animals were
gaining weight. This suggests that PgE2 production is not
involved in the weight loss produced by TNF-x.
Discusio
There is some evidence to suggest that prostaglandins may
be involved in the metabolic effects of TNF-x. An increase
in plasma prostaglandin levels has been observed within 1 h
of TNF-:x administration accompanied by a sharp fall in
body temperature and blood glucose levels (Kettlehut et al.,
1987). Inhibition of prostaglandin production prevented the
hypothermia and changes in blood glucose. Production of
PgE2 is also enhanced after stimulation of mouse osteoblast-
like cells (Sato et al., 1987) and endothelial cells (Dayer et
al., 1985) with TNF-x. Both TNF-x and interleukin I have
been shown to stimulate the production of PgE2 by isolated
extensor digitorum longus muscles (Moldawer et al., 1987a).
An enhanced release of arachidonic acid by TNF-x from
human synovial cells anrses by stimulation of phospholipase
A2 and possibly phospholipase C activity (Godfrey et al.,
1987). In the present study an enhanced production of PgE2
was observed in isolated spleen cells taken from TNF-2
treated animals, which was significantly greater than saline
injected controls within I h of treatment. This suggests that
PgE2 may serve as an intermediate for TNF-x effects,
although PgE2 has also been shown to inhibit TNF-x
production by macrophages (Kunkel et al., 1988), suggesting
a fine control for the regulation of TNF-x production.
A single injection of TNF-:x causes a characteristic weight
loss consisting of a reduction in food and water intake and a
decreased carcass water content. This suggests that at least
some of the short-term weight loss associated with TNF-z
may be due to dehydration. This appears not to arise from
an increased fluid output since TNF-2 treated animals
excrete significantly less fluid than controls.
The stable prostaglandin E2 analogue, 16,16-dimethyl
PgE2, produces weight loss in NMRI mice, which is similar
to that produced by TNF-x in that it is accompanied by
both hypophagia and a decrease in water intake. Body
composition analysis shows a similar decrease in total body
water in PgE2 treated mice as in TNF-:x treated mice.
Indomethacin administration decreases both the weight
loss and dehydration after TNF-:x, suggesting that the
anorectic effect is mediated through a prostaglandin
intermediate. However, Marquet et a]. (1987) showed that,
although indomethacin administered before murine TNF-x
alleviated the toxic side effects in rats, it had no effect on the
excessive wasting produced by high doses of TNF-xz. The
reason for this disparity is not immediately clear, but could
be related to differences between murine and human TNF-:x,
or to the timing of the indomethacin administration, which
in our case required a period of 2h between indomethacin
and TNF-x.
Despite this stringent time requirement for reversal of
weight loss, indomethacin was equally effective in inhibiting
PgE2 production after TNF-x administration at all times
from 0.5 to 2h before TNF-:x. These results suggest that
prostaglandins are not involved in the weight loss induced by
TNF-x.
This is further confirmed by measurement of PgE2
production after chronic administration of TNF-x, when the
animals become resistant to subsequent injections of TNF-:x
after the first 24h (Mahony & Tisdale, 1988). The nature of
this tachyphylaxis is not understood at present, but can be
overcome by increasing dosage to maintain a constant food
intake (Tracey et al., 1988). Despite the inability of repeated
treatment of TNF-a to produce continued weight loss it
appeared to be equally effective in stimulating spleen PgE2
production up to 5 days of treatment. This again confirms
that prostaglandins are not involved in the anorectic effect of
TNF-x. Intracerebroventricular microinfusion of TNF-x has
been shown to supress food intake in rats (Plata-Salaman et
al., 1988), possibly by inhibiting glucose-sensitive neurons in
the lateral hypothalamic area, and this effect alone may be
responsible for the anorexia and weight loss induced by
TNF-x.
Cyclooxygenase inhibitors have been shown to decrease
sodium and water excretion in both man (Haylor, 1980) and
the rat (Haylor & Lote, 1980), resulting in retention of body
fluid. In the present experiments indomethacin had no effect
on urine or faeces production either alone or in the presence
of TNF-x, nor did it cause appreciable fluid retention above
saline infused controls. It did, however, reverse the decrease
in body water content caused by TNF-x and also reversed to
some extent the weight loss. The mechanism of this effect is
currently under investigation.
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